Target
B cell maturation antigen (BCMA)
2 abstracts
Abstract
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,
Abstract
Real-world analysis of belantamab mafodotin (belamaf): Care patterns in relapsed/refractory multiple myeloma.Org: GlaxoSmithKline plc, GSK ONCOLOGY,